Literature DB >> 23085512

Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunction.

Hao Tang1, Kunhong Xiao, Lan Mao, Howard A Rockman, Douglas A Marchuk.   

Abstract

Cardiac troponin I-interacting kinase (TNNI3K) is a cardiac-specific kinase whose biological function remains largely unknown. We have recently shown that TNNI3K expression greatly accelerates cardiac dysfunction in mouse models of cardiomyopathy, indicating an important role in modulating disease progression. To further investigate TNNI3K kinase activity in vivo, we have generated transgenic mice expressing both wild-type and kinase-dead versions of the human TNNI3K protein. Importantly, we show that the increased TNNI3K kinase activity induces mouse cardiac remodeling, and its kinase activity promotes accelerated disease progression in a left-ventricular pressure overload model of mouse cardiomyopathy. Using an in vitro kinase assay and proteomics analysis, we show that TNNI3K is a dual-function kinase with Tyr and Ser/Thr kinase activity. TNNI3K expression induces a series of cellular and molecular changes, including a reduction of sarcomere length and changes in titin isoform composition, which are indicative of cardiac remodeling. Using antisera to TNNI3K, we show that TNNI3K protein is located at the sarcomere Z disc. These combined data suggest that TNNI3K mediates cell signaling to modulate cardiac response to stress.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23085512      PMCID: PMC3535516          DOI: 10.1016/j.yjmcc.2012.10.004

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  43 in total

1.  A functional genetic screen identifies regions at the C-terminal tail and death-domain of death-associated protein kinase that are critical for its proapoptotic activity.

Authors:  T Raveh; H Berissi; M Eisenstein; T Spivak; A Kimchi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Hyperphosphorylation of mouse cardiac titin contributes to transverse aortic constriction-induced diastolic dysfunction.

Authors:  Bryan Hudson; Carlos Hidalgo; Chandra Saripalli; Henk Granzier
Journal:  Circ Res       Date:  2011-08-11       Impact factor: 17.367

3.  Hierarchical phosphorylation within the ankyrin repeat domain defines a phosphoregulatory loop that regulates Notch transcriptional activity.

Authors:  Prathibha Ranganathan; Rodrigo Vasquez-Del Carpio; Fred M Kaplan; Hong Wang; Ashu Gupta; Jeffrey D VanWye; Anthony J Capobianco
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

4.  Adenovirus-mediated overexpression of cardiac troponin I-interacting kinase promotes cardiomyocyte hypertrophy.

Authors:  Lin Wang; Hui Wang; Jue Ye; Rui-Xia Xu; Li Song; Na Shi; Yan-Wan Zhang; Xi Chen; Xian-Min Meng
Journal:  Clin Exp Pharmacol Physiol       Date:  2011-04       Impact factor: 2.557

5.  Quantitative trait loci for electrocardiographic parameters and arrhythmia in the mouse.

Authors:  Brendon P Scicluna; Michael W T Tanck; Carol Ann Remme; Leander Beekman; Ruben Coronel; Arthur A M Wilde; Connie R Bezzina
Journal:  J Mol Cell Cardiol       Date:  2010-09-18       Impact factor: 5.000

6.  Cellular and functional defects in a mouse model of heart failure.

Authors:  G Esposito; L F Santana; K Dilly; J D Cruz; L Mao; W J Lederer; H A Rockman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-12       Impact factor: 4.733

7.  Quantitative trait locus analysis, pathway analysis, and consomic mapping show genetic variants of Tnni3k, Fpgt, or H28 control susceptibility to viral myocarditis.

Authors:  Sean A Wiltshire; Gabriel André Leiva-Torres; Silvia M Vidal
Journal:  J Immunol       Date:  2011-04-27       Impact factor: 5.422

Review 8.  Titin-based regulations of diastolic and systolic functions of mammalian cardiac muscle.

Authors:  Norio Fukuda; Takako Terui; Shin'ichi Ishiwata; Satoshi Kurihara
Journal:  J Mol Cell Cardiol       Date:  2009-12-03       Impact factor: 5.000

Review 9.  TNNI3K could be a novel molecular target for the treatment of cardiac diseases.

Authors:  Zhong-Fang Lai
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2009-11

10.  Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin.

Authors:  Kelly N Nobles; Kunhong Xiao; Seungkirl Ahn; Arun K Shukla; Christopher M Lam; Sudarshan Rajagopal; Ryan T Strachan; Teng-Yi Huang; Erin A Bressler; Makoto R Hara; Sudha K Shenoy; Steven P Gygi; Robert J Lefkowitz
Journal:  Sci Signal       Date:  2011-08-09       Impact factor: 8.192

View more
  13 in total

Review 1.  Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease.

Authors:  Hind Lal; Firdos Ahmad; Shan Parikh; Thomas Force
Journal:  Circ J       Date:  2014-06-05       Impact factor: 2.993

2.  Frequency of mononuclear diploid cardiomyocytes underlies natural variation in heart regeneration.

Authors:  Michaela Patterson; Lindsey Barske; Ben Van Handel; Christoph D Rau; Peiheng Gan; Avneesh Sharma; Shan Parikh; Matt Denholtz; Ying Huang; Yukiko Yamaguchi; Hua Shen; Hooman Allayee; J Gage Crump; Thomas I Force; Ching-Ling Lien; Takako Makita; Aldons J Lusis; S Ram Kumar; Henry M Sucov
Journal:  Nat Genet       Date:  2017-08-07       Impact factor: 38.330

3.  TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy.

Authors:  Jeanne L Theis; Michael T Zimmermann; Brandon T Larsen; Inna N Rybakova; Pamela A Long; Jared M Evans; Sumit Middha; Mariza de Andrade; Richard L Moss; Eric D Wieben; Virginia V Michels; Timothy M Olson
Journal:  Hum Mol Genet       Date:  2014-06-11       Impact factor: 6.150

4.  The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice.

Authors:  Peiheng Gan; Catalin Baicu; Hirofumi Watanabe; Kristy Wang; Ge Tao; Daniel P Judge; Michael R Zile; Takako Makita; Rupak Mukherjee; Henry M Sucov
Journal:  Hum Mol Genet       Date:  2021-01-06       Impact factor: 6.150

5.  Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart.

Authors:  Ronald J Vagnozzi; Gregory J Gatto; Lara S Kallander; Nicholas E Hoffman; Karthik Mallilankaraman; Victoria L T Ballard; Brian G Lawhorn; Patrick Stoy; Joanne Philp; Alan P Graves; Yoshiro Naito; John J Lepore; Erhe Gao; Muniswamy Madesh; Thomas Force
Journal:  Sci Transl Med       Date:  2013-10-16       Impact factor: 17.956

Review 6.  New Myocyte Formation in the Adult Heart: Endogenous Sources and Therapeutic Implications.

Authors:  Ronald J Vagnozzi; Jeffery D Molkentin; Steven R Houser
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

7.  Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level.

Authors:  Xinge Jessie Jeng; Zhongyin John Daye; Wenbin Lu; Jung-Ying Tzeng
Journal:  PLoS Comput Biol       Date:  2016-06-29       Impact factor: 4.475

8.  Quantitative trait loci with sex-specific effects for internal organs weights and hematocrit value in a broiler-layer cross.

Authors:  A S A M T Moura; M C Ledur; C Boschiero; K Nones; L F B Pinto; F R F Jaenisch; D W Burt; L L Coutinho
Journal:  J Appl Genet       Date:  2015-10-24       Impact factor: 3.240

Review 9.  The Diverse Roles of TNNI3K in Cardiac Disease and Potential for Treatment.

Authors:  Caroline Pham; Noelia Muñoz-Martín; Elisabeth M Lodder
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

10.  Tnni3k alleles influence ventricular mononuclear diploid cardiomyocyte frequency.

Authors:  Peiheng Gan; Michaela Patterson; Alexa Velasquez; Kristy Wang; Di Tian; Jolene J Windle; Ge Tao; Daniel P Judge; Takako Makita; Thomas J Park; Henry M Sucov
Journal:  PLoS Genet       Date:  2019-10-07       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.